FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to ophthalmology. The stage of glaucoma, the level of intraocular pressure (IOP level), the progression of POAG according to static perimetry data, the presence of local antihypertensive therapy or selective laser trabeculoplasty (SLT), the tolerance of antihypertensive drugs, the presence of risk factors are assessed, while the suspicion of glaucoma is estimated at 1 point, the initial stage - 2 points, advanced - 4 points, chronic - 6 points. Normal IOP level - 0 points; borderline value of IOP - 1 point; moderately increased - 3 points; high - 5 points. Progression: not detected - 0 points; insufficient data in the absence of 3 studies - 3 points; decrease during the year in VFI less than 1% and MD by less than 0.3 dB - 2 points; decrease in VFI from 1 to 3% and MD by 0.3-1 dB - 4 points; VFI over 3% and MD over 1 dB - 8 points. Local antihypertensive therapy was not previously performed - 0 points, initial therapy - monotherapy with prostaglandin analogs, β-blockers, or α-adrenomimetics, or carbonic anhydrase inhibitors, or SLT - 1 point. Enhanced - monotherapy with prostamides or non-fixed combinations of two monopreparations - 3 points; combined - fixed combinations of an analogue of prostaglandin or prostamide with timolol or a combination of three active topical antihypertensive substances, with the exception of prostamides, in different combinations - 4 points. Maximum - a combination of three active antihypertensive substances, including prostamide, or local antihypertensive therapy, supplemented with systemic drugs - 8 points, tolerance of antihypertensive drugs is good - 0 points, poor - 2 points, absence or one of the risk factors - 0 points, two or more - 2 points. With a score of 0-6, follow-up without treatment, 7-10 - prescribing starting therapy or SLT, 11-13 - intensified therapy, 14-16 - combined antihypertensive therapy, informing the patient about the possibility of surgical treatment, 17-19 - maximum antihypertensive therapy, informing the patient about the possibility of surgical treatment, more than 19 - the appointment of antiglaucoma surgery.
EFFECT: method allows choosing the most optimal and individual tactics for treating a patient with open-angle glaucoma at various stages of the disease.
1 cl, 4 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DETERMINATION OF INDICATIONS FOR PRIMARY OPEN-ANGLE GLAUCOM SURGICAL TREATMENT | 2016 |
|
RU2614971C1 |
METHOD FOR DETERMINING PRIMARY OPEN ANGLE GLAUCOMA TREATMENT TACTICS | 2004 |
|
RU2262882C1 |
METHOD FOR PREDICTING THE RISK OF PROGRESSION OF PRIMARY OPEN-ANGLE GLAUCOMA | 2023 |
|
RU2804591C1 |
METHOD OF PREVENTION OF THE PROGRESSION OF PRIMARY OPEN-ANGLE GLAUCOMA | 2023 |
|
RU2799582C1 |
METHOD FOR DETERMINING THERAPEUTIC APPROACH TO INITIAL STAGE OF PRIMARY OPEN-ANGLE GLAUCOMA | 2018 |
|
RU2681705C1 |
METHOD OF DETERMINATION OF THE STAGE OF PRIMARY OPEN-TINED GLAUCOM | 2016 |
|
RU2616212C1 |
METHOD OF TWO-STAGE SURGICAL TREATMENT OF CATARACT IN COMBINATION WITH PRIMARY OPEN-ANGLE GLAUCOMA | 2022 |
|
RU2796869C1 |
METHOD OF EVALUATING STATE OF OPTIC NERVE IN OPTIC NEUROPATHY OF VARIOUS GENESES | 2015 |
|
RU2585429C1 |
METHOD OF PREVENTING THE PROGRESSION OF PRIMARY OPEN-ANGLE GLAUCOMA | 2022 |
|
RU2796891C1 |
ESTIMATION METHOD OF THE EFFICACY OF NEURORETINO PROTECTION OF PRIMARY OPEN-ANGLE GLAUCOMA ON THE BASIS OF DETERMINATION OF NEURON-SPECIFIC ENOLASE | 2018 |
|
RU2681935C1 |
Authors
Dates
2021-12-02—Published
2021-04-14—Filed